Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Radiation Therapy Oncology Group Stories

2013-09-23 13:58:38

Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The Radiation Oncology Therapy Group (RTOG) Community Clinical Oncology Program (CCOP)-supported multi-institutional study screened 455 patients receiving radiation treatment at 37 centers around the U.S. Participants in the...

2013-09-23 13:16:47

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total...

2013-09-23 13:14:45

Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The single-arm, phase II study was a multi-institutional, international clinical trial in the U.S. and Canada, conducted through the Radiation Therapy...

2013-09-23 13:13:29

Analysis of RTOG 0617 trial evaluates the impact of high-dose radiation therapy An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual...

2013-09-23 08:29:40

Results of a multi-institutional randomized phase II trial (RTOG 0915/NCCTG N0927) presented at the 2013 annual meeting of the American Society for Radiation Oncology (ASTRO) ATLANTA, Sept. 23, 2013 /PRNewswire/ -- Treating inoperable early-stage non-small cell lung cancer (NSCLC) with a single session of stereotactic body radiation therapy (SBRT) may be a viable option in some cases, according to the results of a multi-institutional randomized phase II trial led by the Radiation...

2013-08-20 23:23:18

The affiliation allows further collaboration to advance cancer research. Fort Myers, FL and Scottsdale, AZ (PRWEB) August 20, 2013 21st Century Oncology today announced it will more closely combine cancer research initiatives with Massachusetts General Hospital (MGH), the original and largest teaching affiliate of Harvard Medical School (HMS). Currently, 21st Century Oncology, the largest U.S. radiation therapy provider, conducts cancer research alongside MGH within the framework of the...

2013-06-03 10:48:37

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting. GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the...

2013-05-30 13:48:47

In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC). Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being considered locally advanced...

2013-04-30 10:45:51

'This study confirms that VEGF is not a path forward to tackling this disease' The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology. VEGF, or vascular endothelial growth factor, induces blood...

2012-01-19 20:42:22

A recent analysis of clinical trial results performed by the Radiation Therapy Oncology Group (RTOG) demonstrate that a chromosomal abnormality–specifically, the absence (co-deletion) of chromosomes 1p and 19q–have definitive prognostic and predictive value for managing the treatment of adult patients with pure and mixed anaplastic oligodendrogliomas. The presence of the chromosomal abnormality was associated with a substantially better prognosis and near-doubling of median...